Mirtazapina Aurobindo (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Aurobindo, is a NaSSA presented as an oral tablet for oral use. It is prescribed to treat major depressive disorder in adult patients, helping to improve mood, sleep and appetite, and is often selected when other antidepressants have been ineffective.

GNH USA supplies Mirtazapina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution through.

Mirtazapine is an antidepressant that acts on noradrenergic and serotonergic pathways to alleviate depressive symptoms.

- Major depressive disorder: reduction of depressive symptoms and improvement in overall mood. - Treatment‑resistant depression: augmentation of therapeutic response when other antidepressants have not achieved sufficient effect. - Depression‑related anxiety: alleviation of anxiety symptoms and improvement of sleep quality in patients with co‑occurring anxiety. - Bipolar depression (as adjunct): helps stabilize the depressive phase when used with mood stabilizers. - Insomnia associated with depression: promotes sleep onset and maintenance due to antihistaminic effect.

Mirtazapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior, especially early in treatment

When prescribing mirtazapine, clinicians should consider several precautionary measures to ensure patient safety.

- Assess hepatic function: evaluate liver enzymes before initiating therapy. - Monitor weight: regular checks due to potential significant weight gain. - Evaluate for suicidal ideation: especially during the first weeks of treatment. - Avoid abrupt discontinuation: taper the dose under medical supervision to prevent withdrawal symptoms. - Use caution in elderly patients: increased sensitivity to sedation and orthostatic hypotension. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use may cause hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): risk of serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Anticholinergic drugs (e.g., diphenhydramine): can enhance anticholinergic burden. - Diuretics: may exacerbate orthostatic hypotension.